PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSE
Elizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centeno, Lynn M. Heltemes-Harris, Gregory Hubbard, Taylor L Maiers, Thamotharampillai Dileepan, Sean I. Tracy, Michael A. Farrar
This study compares the effects of nilotinib and dasatinib on anti-leukemia immune responses when combined with PD-L1 blockade, finding that nilotinib synergizes with PD-L1 blockade to prevent relapse while dasatinib does not.
bioRxiv · Jul 2, 2025 · PreprintImmunology